Preclinical study of plasmodium immunotherapy combined with radiotherapy for solid tumors

HIGHLIGHTS

SUMMARY

    ICB, such as PD-1 antibody, removes the inhibitory signal of effector T_cells by blocking the binding of inhibitory receptor (such as PD-1) on the surface of T_cells and inhibitory ligand (such as PD-L1) on the surface of tumor cells, enabling T_cells to kill tumor cells. ICB is usually only effective in hot tumors and is proven non-efficacious for cold tumors as ICB acts by removing the inhibitory signals from tumor infiltrating and residential effector T_cells that have been activated and then suppressed by tumor cells, but it would not work . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?